Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Aileen Chen Image

      Aileen Chen, M.D.

      Department of Thoracic Radiation Oncology, Division of Radiation Oncology

      About Dr. Aileen Chen

      Dr. Aileen Chen received her MD from Harvard Medical School and has a degree in Health Care Policy from the Harvard Kennedy School of Government.  She completed her residency at the Harvard Radiation Oncology Program and was on faculty at the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School until 2018.

      Dr. Chen is currently a member of the Thoracic Radiation Oncology Service and Department of Health Services Research at MD Anderson Cancer Center.  She specializes in the treatment of all types of thoracic cancer, including lung cancer, esophagus cancer, thymoma, and mesothelioma, and is working to improve the effectiveness of radiation therapy, with fewer side effects.  In addition, she has an interest in refining the use of radiation therapy for patients with metastatic disease.  

      Dr Chen's research focuses on improving quality, value, and care experience for patients.  She has published numerous peer-reviewed studies and received funding from the American Cancer Society, the American Society for Radiation Oncology, and NIH/NCI.

      Read More

      Present Title & Affiliation

      Primary Appointment

      Professor, Health Services Research, The University of Texas MD Anderson Cancer Center

      Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2002Harvard JFK School of Government, Cambridge, Massachusetts, US, Health Care Policy, MA, MPP
      2002Harvard Medical School, Boston, Massachusetts, US, Medicine, MD
      1997Harvard College, Cambridge, Massachusetts, US, Applied Mathematics/Economics, MA, AB

      Postgraduate Training

      2006-2007Chief Resident, Radiation Oncology, Harvard Radiation Oncology Program, Boston, Massachusetts
      2003-2007Clinical Residency, Radiation Oncology, Harvard Radiation Oncology Program, Boston, Massachusetts
      2002-2003Clinical Internship, Medicine, Mount Auburn Hospital, Cambridge, Massachusetts

      Licenses & Certifications

      nullAlabama Board of Medical Examiners
      nullOklahoma State Board of Medical Licensure
      nullArizona Board of Medical Examiners
      nullMississippi State Board of Medical Licensure
      nullWashington State Department of Health
      nullLouisiana State Board of Medical Examiners
      nullTennessee Board of Medical Examiners
      nullGeorgia Composite Medical Board
      nullAmerican Board of Radiology
      nullControlled Substance Registration Certificate
      nullTexas Medical Board Physician License
      nullBasic Life Support (BLS)
      nullFlorida Board of Medicine

      Experience & Service

      Faculty Academic Appointments

      Associate Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024

      Associate Professor, Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024

      Assistant Professor, Harvard Medical School, Boston, MA, 2011 - 2018

      Instructor, Harvard Medical School, Boston, MA, 2007 - 2011

      Administrative Appointments/Responsibilities

      Associate Administrative Director, Radiation Oncology, Radiation Oncology Strategic Initiative, Value, Access, and Quality Platform, Houston, Texas, 2023 - Present

      Quality and Safety Officer, Radiation Oncology, Department of Thoracic Radiation Oncology, Houston, Texas, 2023 - Present

      Committee Chair, Radiation Oncology-Research, Radiation Oncology Clinical Research Council Data Governance, Houston, Texas, 2019 - Present

      Associate Administrative Director, Radiation Oncology, Radiation Oncology Strategic Initiative, Health Services Research Platform, Houston, TX, 2018 - 2023

      Chest and Lung Cancer Affinity Group Leader, Brigham and Women's Hospital, Boston, MA, 2015 - 2018

      Thoracic Disease Site Leader, Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, 2012 - 2018

      Other Professional Positions

      Physician Advisor, Radiation Oncology Model - Implementation and Monitoring contract, Mathematica/Center for Medicare and Medicaid Innovation, Washington, DC, 2021 - 2022

      Episode-based Cost Measure Oncologic Disease Management Subcommittee, Medicare Access and CHIP Reauthorization Act (MACRA), Washington, DC, 2018 - 2019

      Clinical Coverage Redesign Committee (Organizer), Dana-Farber/Brigham and Women's Hospital, Department of Radiation Oncology, Boston, MA, 2017

      Health Policy Fellowship, American Society for Radiation Oncology, Arlington, VA, 2016 - 2017

      Thoracic OncoPanel User Committee, Dana-Farber Cancer Center Thoracic Oncology Program, Bo, MA, 2015 - 2018

      Senior Physician, Dana-Farber Cancer Institute, Boston, MA, 2015 - 2018

      Research Subcommittee, Partners eCare Patient Engagement Committee, Boston, MA, 2014 - 2015

      Lung Cancer Working Group, International Consortium for Health Outcomes Measurement, Boston, MA, 2014 - 2015

      Career Development Committee, Dana-Farber/Harvard Cancer Center Lung Cancer SPORE, Boston, MA, 2013 - 2018

      Director, Thoracic Radiation Oncology Program, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, 2012 - 2018

      Faculty Search Committee, Dana-Farber Cancer Center Department of Medical Oncology, Boston, MA, 2011 - 2017

      Member, Women's Lung Cancer Program, Boston, MA, 2010 - 2018

      Steering Committee, Harvard Medical Physics Residency Program, Boston, MA, 2009 - 2018

      Treatment Planning Committee, Department of Radiation Oncology, Boston, MA, 2008 - 2018

      Associate Physician, Brigham and Women's Hospital, Boston, MA, 2007 - 2018

      Physician, Dana-Farber Cancer Institute, Boston, MA, 2007 - 2015

      Instructor, Department of Radiation Oncology, Harvard Medical School, Dana-Farber Cancer Institute, and Brigham and Women's Hospital, Boston, MA, 2007 - 2011

      Extramural Institutional Committee Activities

      Moderator, Institutional Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, Credentialing Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Member, Cancer Survivorship Clinical Care Workgroup, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Member, Cancer Survivorship Steering Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Co-Leader, Particle Therapy Taskforce: Value, The University of Texas MD Anderson Cancer Center, 2022 - 2024

      Chair, Radiation Oncology Space Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2024

      Member, Radiation Oncology Informatics Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

      Member, Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023

      Member, Nanobiotix Alliance Safety Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Member, QOL-PRO Implementation Workgroup, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Radiation Oncology Mentoring Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Radiation Oncology Finance Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      HSR Expert, Protocol in a Day Workshop, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Psychosocial Behavioral and Health Services Research Scientific Review, The University of Texas MD Anderson Cancer Center, 2019 - 2021

      Editorial Activities

      Senior Editor, Practical Radiation Oncology, 2018 - 2020

      Honors & Awards

      2024ASTRO Fellow, American Society for Radiation Oncology
      2022Mid-Career Women Faculty Leadership Development Seminar, Association of American Medical Colleges
      2014Outstanding Poster Award, Brigham Research Institute Patient Centered Comparative Effectiveness Research Center
      2007Resident Clinical Basic Science Research Award, American Society for Radiation Oncology
      2006Merit Award, American Society of Clinical Oncology
      2006Travel Grant, American Society for Radiation Oncology Health Services/Outcomes Research in Oncology
      2000 - 2002Knowles Fellowship, Harvard JFK School of Government
      1998 - 2002Teagle Foundation Scholarship, Teagle Foundation
      1998 - 1999Student Research Fellowship, Harvard Medical School
      1998Paul D. White Fellowship, Harvard Medical School
      1997Phi Beta Kappa, Harvard College

      Professional Memberships

      International Association for the Study of Lung Cancer

      2023 - 2024

      Education Committee Lung, American Society of Radiation Oncology

      2019 - 2022

      International Association for the Study of Lung Cancer

      2019 - 2020

      Comparative Effectiveness Research Resource Panel, American Society of Radiation Oncology

      2017 - Present

      Palliative Thoracic Radiation Guideline Workgroup, American Society of Radiation Oncology

      2016 - 2018

      Health Policy Committee, Code Development and Valuation, American Society of Radiation Oncology

      2015 - Present

      Education Committee - Lung, American Society of Radiation Oncology

      2014 - 2019

      Payment Reform Workgroup, American Society of Radiation Oncology

      2014 - 2016

      Emerging Technology Monitoring Subcommittee, American Society of Radiation Oncology

      2014 - 2015

      Annual Meeting Track - Patient Reported Outcomes/QoL/Survivorship

      2013 - 2025

      Annual Meeting Track - Lung Cancer/Thoracic Malignancies

      2013 - 2025

      Science Workshops Committee, American Society of Radiation Oncology

      2013 - 2014

      Scientific Program Committee, American Society of Radiation Oncology

      2010 - 2013

      American Society of Radiation Oncology

      2009 - Present

      International Association for the Study of Lung Cancer

      2009 - 2011

      International Conference on Metastases, American Society of Radiation Oncology

      2009 - 2010

      Health Services Research Committee, American Society of Radiation Oncology

      2008 - 2013

      American Society for Women Radiologists

      2007 - 2010

      American Brachytherapy Society

      2005 - 2007

      American Society of Clinical Oncology

      2003 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2024. Multidisciplinary care discussion panel. Conference. Houston, Texas, US.
      2. 2024. Assessing the needs of incurable lung cancer survivors. Conference. Houston, Texas, US.
      3. 2023. Lessons Learned. Conference. Houston, Texas, US.
      4. 2023. Multidisciplinary care discussion panel. Conference, US.
      5. 2022. Tumor-treating fields in non-small cell lung cancer. Conference. Tumor-treating fields research and development day, US.
      6. 2022. Multidisciplinary care discussion panel. Conference, US.
      7. 2018. Challenges in value-based care for radiation oncology. Conference. Houston, TX, US.

      National Presentations

      1. 2023. Developing a PRO toolkit for radiation oncology. Conference. Washington DC, US.
      2. 2023. Clinical trials versus clinical practice: real-world barriers to care for thoracic patients. Conference. Lake Buena Vista, FL, US.
      3. 2022. Mesothelioma staging and workup (education session faculty). Conference. San Antonio, TX, US.
      4. 2021. Practical radiation oncology: lung SBRT. Conference. Chicago, IL, US.
      5. 2021. Radiation oncology alternative payment model: model requirements. Conference, US.
      6. 2021. Radiation oncology alternative payment model: clinical data elements and quality measures. Conference, US.
      7. 2021. Stereotactic radiation for early stage lung cancers (education session faculty). Conference. Chicago, IL, US.
      8. 2020. Radiation for oligometastatic lung cancers. Conference. Houston, TX, US.
      9. 2019. Treating the patient: patient reported outcomes (discussant). Conference. Chicago, IL, US.
      10. 2018. New combinations of radiation and systemic therapies in lung cancer (education session faculty). Conference. San Antonio, TX, US.
      11. 2018. New combinations of radiation and systemic therapies in lung cancer (education session faculty). Conference. San Antonio, TX, US.
      12. 2018. Network tumor boards: thoracic oncology. Conference. Boston, MA, US.
      13. 2017. Advances in radiation therapy for locally advanced lung cancer (education session faculty). Conference. San Diego, CA, US.
      14. 2017. An overview of health outcomes measures to inform value assessments (presidential symposium faculty). Conference. San Diego, TX, US.
      15. 2017. Benchmarking costs and value: The CPT and RUC process in the U.A. (education session faculty). Conference. San Diego, CA, US.
      16. 2017. Challenging cases in comparative effectiveness research (education session faculty). Conference. San Diego, CA, US.
      17. 2016. Meeting the payment reform challenge: a collaboration between a specialty society and health policy researchers. Conference. Dartmouth, NH, US.
      18. 2016. Innovations and challenges in lung cancer radiation therapy. Conference. Center of Excellence - Women's Cancer and Lung Cancer. Boston, MA, US.
      19. 2016. Lung cancer management: radiation oncology. Conference. Chest Imaging Course. Boston, MA, US.
      20. 2016. Using comparative effectiveness evidence to demonstrate value in radiation oncology (education session faculty). Conference. Boston, MA, US.
      21. 2016. Total medicare and radiation-specific costs during a palliative "radiation episode" (oral abstract). Conference. Boston, MA, US.
      22. 2015. How should we estimate costs of care attributable to cancer (oral abstract). Conference. Chicago, IL, US.
      23. 2015. Implications of value-based payment models on oncology practice. Conference. Breast Cancer: New Horizons, Current Controversies. Boston, MA, US.
      24. 2015. Health services research (oral scientific session). Conference. San Antonio, TX, US.
      25. 2015. Payment reform initiatives in radiation oncology, (Education session faculty). Conference. San Antonio, TX, US.
      26. 2014. Patient reported outcomes (oral scientific session). Conference. San Francisco, CA, US.
      27. 2014. Understanding the new evidence: a comparative effectiveness research primer for the radiation oncologist: comparative effectiveness research applications in radiation oncology (education session faculty). Conference. San Francisco, CA, US.
      28. 2013. SBRT for early stage lung cancers. Conference. Bangor, ME, US.
      29. 2013. Radiation treatment of CNS metastases. Conference. Case discussions. Boston, MA, US.
      30. 2013. Health service research (oral abstract session chair). Conference. Chicago, IL, US.
      31. 2013. Patient reported outcomes - head & neck, thoracic and breast cancer (oral scientific session co-moderator. Conference. Atlanta, GA, US.
      32. 2013. Multimodality therapy options for locally advanced disease. Conference. Case discussions. Boston, MA, US.
      33. 2013. Best of health services research. Conference. Best of health services research. Boston, MA, US.
      34. 2012. External beam RT, IMRT, SBRT, hypofractionated RT - When each should be used. Conference. Panel discussion. Boston, MA, US.
      35. 2012. Treating brain metastases in NSCLC and SCLC. Conference. Case discussions. Boston, MA, US.
      36. 2012. Health services research poster discussion session chair. Conference. Chicago, IL, US.
      37. 2012. Molecular radiation therapy planning with PET/CT: PET-CT for radiation therapy planning in lung cancer (SAM session). Conference. Miami, FL, US.
      38. 2012. Patient beliefs about palliative radiation therapy in incurable lung cancer (plenary abstract). Conference. Boston, MA, US.
      39. 2011. Outcomes/health services research oral scientific session co-moderator. Conference. Miami, FL, US.
      40. 2010. Patterns of care in the management of stage III non-small cell lung cancer in medicare population (oral abstract). Conference. San Diego, CA, US.
      41. 2008. Radiation therapy: post -extrapleural pneumonectomy strategies. Conference. Dallas, TX, US.
      42. 2006. Provider case volume and outcomes following prostate brachytherapy (oral abstract). Conference. Philadelphia, PA, US.

      International Presentations

      1. 2020. Time to generate new NTCP models based on PROMs?. Conference. Vienna, AT.
      2. 2016. Advances in radiation for lung cancer. Conference, BR.

      Formal Peers

      1. 2023. Living beyond cancer: lung cancer session. Invited, TX, US.
      2. 2023. Lung cancer survivorship: case discussion. Invited, US.
      3. 2022. Management of non-small cell lung cancer and advances in radiation therapy. Invited, ZM.
      4. 2022. Lung cancer survivorship. Invited, US.
      5. 2022. Small-cell lung cancer: Treatment overview. Invited, ZM.
      6. 2021. SBRT for early stage lung cancers. Invited, US.
      7. 2021. Radiation for small-cell lung cancer. Invited, ZM.
      8. 2021. Radiation oncology model: clinical data elements and quality measures reporting requirements. Invited, US.
      9. 2021. Radiation oncology model requirements. Invited, US.
      10. 2021. Radiation oncology practice and impact of payment models. Invited. Cambridge, MA, US.
      11. 2020. Non-small cell lung cancer. Invited, ZM.
      12. 2018. Should we be using more or less palliative radiation for bone metastases? Radiation Oncology Research Showcase. Invited. Boston, MA, US.
      13. 2018. Radiation therapy for lung cancer. Invited, BM.
      14. 2016. The Dartmouth Institute for Health Policy and Clinical Practice. Invited, US.
      15. 2016. Medicare spending and new payment models in radiation therapy, Outcomes Research Program Seminar. Invited. Boston, MA, US.
      16. 2015. How should we estimate costs of cancer care, Outcomes Research Program Seminar. Invited. Boston, MA, US.
      17. 2014. Assessing the use of radiation oncology technologies using population-based data, Program in Cancer Outcomes Research Training Seminar. Invited. Boston, MA, US.
      18. 2014. Assessing effectiveness and costs of radiation therapy using SEER-Medicare, Outcomes Research Program Seminar. Invited. Boston, MA, US.
      19. 2012. Palliative radiation therapy in incurable lung cancer: practice and beliefs, Department of Radiation Oncology Departmental Presentation. Invited. Boston, MA, US.
      20. 2012. Use of intensive therapies in advanced non-small cell lung cancer patients, Outcomes Research Program Seminar. Invited. Boston, MA, US.
      21. 2010. Palliative radiation therapy practice in patients with stage IV lung cancer: a CanCORS analysis, Outcomes Research Program Seminar. Invited. Boston, MA, US.
      22. 2010. Palliative radiation for metastatic non-small cell lung cancer, Thoracic Oncology Program Seminar. Invited. Boston, MA, US.
      23. 2009. Using of radiation therapy technologies for lung cancer, Outcomes Research Program Seminar. Invited. Boston, MA, US.
      24. 2009. Advances in imaging technology for lung cancer radiation, Thoracic Oncology Program Seminar. Invited. Boston, MA, US.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - 2028
      Title:Leveraging patient-reported outcomes and medical record data to predict outcomes in lung cancer patients and survivors
      Funding Source:National Institutes of Health (NIH)
      Role:PI
      Date: 2023 - Present
      Title:Quality of life and needs of advanced lung cancer survivors
      Funding Source:MDACC Survivorship IRG
      Role:PI
      Date: 2023 - 2028
      Title:Psycho-Spiritual Management for Patients with Advanced Cancer and their Family Caregivers
      Funding Source:NIH/NCI
      Role:CO-I
      ID:5R01CA276035-03
      Date: 2023 - 2027
      Title:Development of a PRO implementation toolkit for radiation oncology
      Funding Source:Pfizer Global Medical Grants
      Role:PI
      ID:FP00017425
      Date: 2022 - 2024
      Title:Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTF) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic NSCLC
      Funding Source:Novocure
      Role:Principal Investigator-MDACC
      Date: 2021 - 2023
      Title:mPROS- Mobile PRO-CTCAE Administration System for Post-Radiation Toxicities
      Funding Source:NIH/NCI
      Role:Principal Investigator-MDACC
      ID:75N91020C00027
      Date: 2017 - 2018
      Title:Adherence to national guidelines for brain imaging among patients with early stage lung cancers
      Funding Source:Harvard Medical School Student Research Grant
      Role:Student
      Date: 2014 - 2019
      Title:A high efficiency imager for real-time lung cancer monitoring during radiotherapy
      Funding Source:NIH/NCI
      Role:CO-I
      ID:1R01CA188446-01
      Date: 2014 - 2016
      Title:Exploratory analysis of the SEER-Medicare dataset to estimate cost of cancer treatment
      Funding Source:American Society for Radiation Oncology
      Role:PI
      Date: 2014 - 2016
      Title:Improving physician-patient communication regarding goals of radiation therapy
      Funding Source:Gloria Spivak Faculty Advancement Fund
      Role:PI
      Date: 2013 - 2015
      Title:Comparative effectiveness of advanced radiation therapy technologies for lung cancer
      Funding Source:Gloria Spivak Faculty Advancement Fund
      Role:PI
      Date: 2013 - 2014
      Title:Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer
      Funding Source:Harvard Medical School Student Research Grant
      Role:Mentor
      Date: 2010 - 2013
      Title:Use of palliative radiation in patients with stage IV lung cancer (awared-declined due to overlap)
      Funding Source:American Lung Association Social Behavioral Research
      Role:PI
      Date: 2010 - 2013
      Title:Use of palliative radiation in patients with stage IV lung cancer
      Funding Source:American Cancer Society Mentored Research Scholar Grant
      Role:PI
      Date: 2009 - 2011
      Title:Management of locally advanced lung cancer in the elderly
      Funding Source:Joint Center of Radiation Therapy Foundation
      Role:PI
      Date: 2008 - 2009
      Title:Use of radiation planning and treatment technologies in lung cancer, DFCI 08-139
      Funding Source:Joint Center for Radiation Therapy Foundation Grant
      Role:PI
      Date: 2008 - 2009
      Title:Infrared marker protocol-thoracic cohort
      Funding Source:Kaye Grant
      Role:PI

      Selected Publications

      Peer-Reviewed Articles

      1. Yamashita, K, Kwiatkowski, E, Sewastjanow-Silva, M, Rogers, JE, Yoshimura, K, Pizzi, M, Gan, Q, Li, JJ, Waters, R, Murphy, MB, Iwatsuki, M, Hofstetter, WL, Chen, A, Yuan, Y, Ajani, JA. Clinical Machine Learning Model for Predicting Pathological Complete Response in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma After Trimodality Therapy. Annals of surgical oncology 33(8):7133-7141, 2026. e-Pub 2026. PMID: 42002713.
      2. Lin, R, Chen, M, Zhang, X, Xu, T, Xu, T, Maguire, RC, Corrigan, KL, Koutroumpakis, E, Chang, JY, Lin, SH, Chen, A, Nguyen, Q, Gandhi, S, Ning, M, Bronk, JK, Chun, SG, Ajdari, A, Niedzielski, JS, Yang, J, Chen, X, Pan, T, Meng, QH, Tsao, A, Deswal, A, Mohan, R, Liao, Z. Bayesian Learning to Reduce Cardiac Risk of Patients With Locally Advanced Non-Small Cell Lung Cancer Based on Personalized Radiation Therapy Prescription. International Journal of Radiation Oncology Biology Physics 125(3):949-958, 2026. e-Pub 2026. PMID: 41365476.
      3. Xu X, Saad MB, Grippin A, Xu H, Muneer A, Young E, Lin SH, Liao Z, Gandhi S, Balter P, Ning MS, Qian D, Bronk JK, Chen A, O'Reilly M, Nguyen QN, Welsh J, Pollard-Larkin JM, Heymach JV, Lee JJ, Wu J, Chang JY. SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With Radiotherapy. J Thorac Oncol:103956, 2026. e-Pub 2026. PMID: 42229634.
      4. Su T, Xu T, Chen M, Chen X, Nguyen QN, Chun SG, Lin SH, Chang JY, Heymach JV, Tsao A, Deswal A, Koutroumpakis E, Qian D, Bronk J, Ning M, Chen A, O'Reilly M, Gandhi S, Fossella FV, Blumenschein GR Jr, Vaporciyan AA, Swisher SG, Lu CS, Mohan R, Zhang X, Lee JJ, Liao Z. Long-Term Outcomes After Proton Therapy Versus Intensity Modulated Photon Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Post Hoc Analysis of a Prospective Randomized Trial. Int J Radiat Oncol Biol Phys, 2026. e-Pub 2026. PMID: 42173326.
      5. Pearce JB, Pandey P, Hassanzadeh C, Smith BD, Chen A, Kemp A, Bird J, Patel SS, Satcher R, Lin PP, Colbert LE, Mitchell M, Grosshans D. Preoperative radiotherapy for appendicular bone metastases: outcomes. BMJ Support Palliat Care, 2026. e-Pub 2026. PMID: 41771703.
      6. Eversole, EA, Cha, E, Al-Sharfeen, A, Chen, A, Marquez, C, Peek, A, Peterson, SK, Lowenstein, LM, Swanson, DM, Klopp, AH, Lin, LL. Patient-reported outcomes as a tool for enhanced symptom management in gynecologic radiation oncology 21:388, 2025. e-Pub 2025.
      7. Eversole, EA, Cha, E, Alatrach, M, Marquez, C, Peek, A, Lin, LL, Lowenstein, LM, Peterson, SK, Swanson, DM, Liao, Z, Chen, A. Leveraging patient-reported outcomes for enhanced symptom management among thoracic radiation patients 21:381, 2025. e-Pub 2025.
      8. Odwuor, A, Lee, PP, Chang, JY, Gandhi, S, Liao, Z, Lin, SH, Chen, A, Nguyen, Q, O'Reilly, M, Chun, SG, Bronk, JK, Qian, DC, Ning, M. Outcomes and Toxicity following 3 or More Definitive Courses of Thoracic Radiation Therapy for Non-Small Cell Lung Cancer. Clinical Lung Cancer 26(5):384-392, 2025. e-Pub 2025. PMID: 40318943.
      9. Dudzinski, SO, Cabanillas, ME, Hamidi, S, Marczyk, VR, Busaidy, NL, Dadu, R, Welsh, J, Hu, MI, Gunn, GB, Wang, C, Waguespack, SG, Phan, J, Beckham, TH, Chang, JY, Sherman, SI, Reddy, JP, Ying, AK, O'Reilly, M, Chen, A, Lee, A, Gandhi, S, Liao, Z, Ludmir, EB, Nguyen, Q, Lin, SH, Zafereo, M, Ning, M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2025. e-Pub 2025. PMID: 39662038.
      10. Ning MS, Odwuor A, Chang JY, Gandhi S, Liao Z, Lin SH, Chen A, Welsh JW, Nguyen QN, O'Reilly MS, Chun SG, Bronk J, Qian D, Lee P. Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. Cancers (Basel) 16(21), 2024. e-Pub 2024. PMID: 39518028.
      11. Chang JY, Xu X, Shroff GS, Comeaux NI, Li W, Rodon Ahnert J, Karp DD, Dumbrava EE, Verma V, Chen A, Welsh J, Hong DS. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39384194.
      12. Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen QN, Liao Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol 193:110121, 2024. e-Pub 2024. PMID: 38311031.
      13. Kroll, JL, Jones, M, Chen, A, Carmack, CL, Cohen, L, Milbury, K. Adult attachment in couples facing stage IV lung cancer: associations with patient quality of life outcomes and sense of life completion. Journal of Psychosocial Oncology Research and Practice 5(3), 2023. e-Pub 2023.
      14. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
      15. Kroll JL, Jones M, Chen AB, Yang CC, Carmack CL, Cohen L, Bruera E, Milbury K. End-of-Life Care, Symptom Burden, and Quality of Life in Couples Facing Stage IV Lung Cancer: The Role of Patient and Spousal Psychospirituality and Discussions Around Fear of Death and Disease Progression. J Palliat Med 26(5):690-696, 2023. e-Pub 2023. PMID: 36856536.
      16. Wandrey NE, Gao D, Robin TP, Contessa JN, Singh C, Chiang V, Li J, Chen A, Wang Y, Sheehan JP, Dutta SW, Weiss SE, Paly J, Rusthoven CG. Multicenter analysis of stereotactic radiosurgery for multiple brain metastases from EGFR and ALK driven non-small cell lung cancer. Lung Cancer 176:144-148, 2023. e-Pub 2023. PMID: 36641932.
      17. Chen JJ, Roldan CS, Nichipor AN, Balboni TA, Krishnan MS, Revette AC, Chen AB, Hertan LM. Prognostic Understanding and Goals of Palliative Radiotherapy: A Qualitative Study. J Pain Symptom Manage 64(6):567-576, 2022. e-Pub 2022. PMID: 36007684.
      18. Xu T, Wu L, Gandhi S, Jing W, Nguyen QN, Chen A, Chang JY, Nurieva R, Sheshadri A, Altan M, Lee PP, Lin SH, Liao Z. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol 176:149-156, 2022. e-Pub 2022. PMID: 36209942.
      19. Snyder S, Kroll JL, Chen AB, Antonoff MB, Yang CC, Milbury K. Moderators of the association between stigma and psychological and cancer-related symptoms in women with non-small cell lung cancer. Psychooncology 31(9):1581-1588, 2022. e-Pub 2022. PMID: 35726392.
      20. De B, Fu S, Chen YS, Das P, Ku K, Maroongroge S, Woodhouse KD, Hoffman KE, Nguyen QN, Reed VK, Chen AB, Koong AC, Smith BD, Smith GL. Patient, physician, and policy factors underlying variation in use of telemedicine for radiation oncology cancer care. Cancer Med 11(10):2096-2105, 2022. e-Pub 2022. PMID: 35297210.
      21. Kroll JL, Kim S, Cho D, Weathers SP, Chen AB, Smith G, Bruera E, Milbury K. Financial distress and its associated burden in couples coping with an advanced cancer. Support Care Cancer 30(5):4485-4495, 2022. e-Pub 2022. PMID: 35112209.
      22. Lin SH, Liao K, Lei X, Verma V, Shaaban S, Lee P, Chen AB, Koong AC, Hoftstetter WL, Frank SJ, Liao Z, Shih YT, Giordano SH, Smith GL. Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. Int J Part Ther 9(1):18-27, 2022. e-Pub 2022. PMID: 35774487.
      23. Chen JJ, Roldan CS, Nichipor AN, Balboni TA, Krishnan MS, Revette AC, Hertan LM, Chen AB. Patient-Provider Communication, Decision-Making, and Psychosocial Burdens in Palliative Radiotherapy: A Qualitative Study on Patients' Perspectives. J Pain Symptom Manage 62(3):512-522, 2021. e-Pub 2021. PMID: 33556491.
      24. Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol 28:54-61, 2021. e-Pub 2021. PMID: 33778173.
      25. Grant SR, Smith BD, Colbert LE, Nguyen QN, Yu JB, Lin SH, Chen AB. National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer. J Natl Compr Canc Netw:1-6, 2021. e-Pub 2021. PMID: 34044365.
      26. Chen AB, Niu J, Cronin AM, Shih YT, Giordano S, Schrag D. Variation in Use of High-Cost Technologies for Palliative Radiation Therapy by Radiation Oncologists. J Natl Compr Canc Netw 19(4):421-431, 2021. e-Pub 2021. PMID: 33578375.
      27. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol 16(2):269-277, 2021. e-Pub 2021. PMID: 33198942.
      28. Milbury K, Kroll J, Chen A, Antonoff MB, Snyder S, Higgins H, Yang CC, Li Y, Bruera E. Pilot Randomized Controlled Trial in Women With Non-Small Cell Lung Cancer to Assess the Feasibility of Delivering Group-Based Psychosocial Care via Videoconference. Integr Cancer Ther 20:15347354211052520, 2021. e-Pub 2021. PMID: 34663123.
      29. Mesko S, Ning MS, Lakomy D, Verma V, Chang JY, O'Reilly M, Jeter MD, Gandhi SJ, Lin SH, Nguyen QN, Liao Z, Welsh J, Chen AB, Hahn S, Gomez DR. Thoracic radiation oncology clinical trial accrual and reasons for nonenrollment: Results of a large, prospective, multiyear analysis. Int J Radiat Oncol Biol Phys 107(5):897-908, 2020. e-Pub 2020. PMID: 32360653.
      30. Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, Hoffman KE, Chapin BF, Kuban DA, Anscher M, Tina Shih YC, Frank SJ, Smith BD. Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Pract Radiat Oncol 10(4):282-292, 2020. e-Pub 2020. PMID: 32298794.
      31. Ayoub Z, Ning MS, Brooks ED, Kang J, Welsh JW, Chen A, Gandhi S, Heymach JV, Vaporciyan AA, Chang JY. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 107(2):261-269, 2020. e-Pub 2020. PMID: 32044413.
      32. Milligan MG, Cronin AM, Colson Y, Kehl K, Yeboa DN, Schrag D, Chen AB. Overuse of diagnostic brain imaging among patients with stage IA non-small cell lung cancer. J Natl Compr Canc Netw 18(5):547-554, 2020. e-Pub 2020. PMID: 32380461.
      33. Yu JB, Brock KK, Campbell AM, Chen AB, Diaz R, Escorcia FE, Gupta G, Hrinivich WT, Joseph S, Korpics M, Onderdonk BE, Pandit-Taskar N, Wood BJ, Woodward WA. Proceedings of the ASTRO-RSNA oligometastatic disease research workshop. Int J Radiat Oncol Biol Phys, 2020. e-Pub 2020. PMID: 32434040.
      34. Raldow AC, Sher D, Chen AB, Punglia RS. Cost effectiveness of DCISionRT for guiding treatment of ductal carcinoma in situ. JNCI Cancer Spectr 4(2):pkaa004, 2020. e-Pub 2020. PMID: 32211582.
      35. Kamran SC, Coroller T, Milani N, Agrawal V, Baldini EH, Chen AB, Johnson BE, Kozono D, Franco I, Chopra N, Zeleznik R, HJWL A, Mak R. The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer. Radiat Oncol 15(1):14, 2020. e-Pub 2020. PMID: 31937336.
      36. Moreno AC, Fellman B, Hobbs BP, Liao Z, Gomez DR, Chen AB, Hahn SM, Chang JY, Lin SH. Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage non-small cell lung cancer. J Thorac Oncol, 2020. e-Pub 2020. PMID: 31479748.
      37. Lin JQ, Li SQ, Pezzi TA, Mohamed ASR, Fuller CD, Chen AB, Minsky BD, Schwartz DL, Hernandez BY, Chun SG. Brief Report: Veterans affairs insurance disparities for metastatic lung cancer in the Hawaiian Island. JTO Clin Res Rept, 2020. e-Pub 2020.
      38. Atkins KM, Rawal B, Chaunzwa TL, Lamba N, Bitterman DS, Williams CL, Kozono DE, Baldini EH Chen AB, Nguyen PL, D'Amico AV, Nohria A Hoffmann U, HJWL A, Mak RJ. Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J AM Coll Cardiol 73(23):2976-2987, 2019. e-Pub 2019. PMID: 31196455.
      39. Raldow AC, Chen AB, Russell M, Lee PP, Hong TS, Ryan DP, Cusack JC, Wo JY. Cost-effectiveness of short-course radiation therapy vs long-course chemoradiation for locally advanced rectal cancer. JAMA Netw Open 2(4):e192249, 2019. e-Pub 2019. PMID: 30977859.
      40. Chen AB, Li L, Cronin AM, Brooks GA, Kavanagh BD, Schrag D. Estimating costs of care attributable to cancer: does the choice of comparison group matter?. Health Serv Res 53 Suppl 1:3227-3244, 2018. e-Pub 2018. PMID: 28858372.
      41. Moeller B, Balagamwala EH, Chen AB, Creach KM, Giaccone G, Koshy M, Zaky S, Rodrigues G. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. Pract Radiat Oncol 8(4):245-250, 2018. e-Pub 2018. PMID: 29625898.
      42. Lam MB, Li L, Cronin A, Schrag D, Chen AB. Palliative radiation and fractionation in medicare patients with incurable non-small cell lung cancer. Adv Radiat Oncol 3(3):382-390, 2018. e-Pub 2018. PMID: 30202806.
      43. Hou Y, Hermann G, Lewis JH, Aerts HJ, Baldini EH, Chen AB, Colson YL, Hacker FL, Killoran JH, Kozono DE, Wagar M, Wee JO, Mak RH. Clinical outcomes after lung stereotactic body radiation therapy in patients with or without a prior lung resection. Am J Clin Oncol 41(7):695-701, 2018. e-Pub 2018. PMID: 27819875.
      44. Franco I, Chen YH, Chipidza F, Agrawal V, Romano J, Baldini E, Chen AB, Colson Y, Hou Y, Kozono D, Wee J, Mak R. Use of frailty to predict survival in elderly patients with early stage non-small-cell lung cancer treated with stereotactic body radiation therapy. J Geriatr Oncol 9(2):130-137, 2018. e-Pub 2018. PMID: 28941581.
      45. Wang EH, Corso CD, Park HS, Chen AB, Wilson LD, Kim AW, Decker RH, Yu JB. Association between radiation dose and outcomes with postoperative radiotherapy for N0-N1 non-small cell lung cancer. Am J Clin Oncol 41(2):152-158, 2018. e-Pub 2018. PMID: 26523443.
      46. Diao K, Chen YH, Catalano PJ, Lee S, Milani N, Killoran JH, Baldini EH, Chen AB, Kozono DE, Mak RH. Radiation toxicity in patients with collagen vascular disease and intrathoracic malignancy treated with modern radiation techniques. Radiother Oncol 125(2):301-309, 2017. e-Pub 2017. PMID: 29102264.
      47. Royce TJ, Punglia RS, Chen AB, Patel SA, Thornton KA, Raut CP, Baldini EH. Cost-effectiveness of surveillance for distant recurrence in extremity soft tissue sarcoma. Ann Surg Oncol 24(11):3264-3270, 2017. e-Pub 2017. PMID: 28718037.
      48. Hou Y, Lee S, Agrawal V, Romano J, Baldini EH, Chen AB, Kozono DE, Killoran JH, Wagar M, Hacker FL, Aerts HJ, Lewis JH, Mak RH. Inter-scan and inter-observer tumor volume delineation variability on cone beam computed tomography in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer. J Med Imaging Radiat Oncol 61(1):93-98, 2017. e-Pub 2017. PMID: 27709803.
      49. Agrawal V, Coroller TP, Hou Y, Lee SW, Romano JL, Baldini EH, Chen AB, Kozono D, Swanson SJ, Wee JO, HJWL A, Mak RH. Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC. PLoS One 12(4):e0174268, 2017. e-Pub 2017. PMID: 28426673.
      50. Chen AB, Lyatskaya Y, Killoran JH, Boyd M, Singh S, Kaplin S, Allen A. Prospective study of infared-guided patient setup for fractonated thoracic radiation. Int J Med Phys Clin Eng Radiat Oncol 6:313-322, 2017. e-Pub 2017.
      51. Agrawal V, Coroller TP, Hou Y, Lee SW, Romano JL, Baldini EH, Chen AB, Jackman DM, Kozono D, Swanson SJ, Wee JO, Aerts HJ, Mak RH. Radiologic-pathologic correlation of response to chemoradiation in resectable locally advanced NSCLC. Lung Cancer 102:1-8, 2016. e-Pub 2016. PMID: 27987576.
      52. Raldow AC, Sher D, Chen AB, Recht A, Punglia RS. Cost effectiveness of the oncotype DX DCIS score for guiding treatment of patients with ductal carcinoma in situ. J Clin Oncol 34(33):3963-3968, 2016. e-Pub 2016. PMID: 27621393.
      53. Mak KS, van Bommel AC, Stowell C, Abrahm JL, Baker M, Baldotto CS, Baldwin DR, Borthwick D, Carbone DP, Chen AB, Fox J, Haswell T, Koczywas M, Kozower BD, Mehran RJ, Schramel FM, Senan S, Stirling RG, van Meerbeeck JP, Wouters MW, Peake MD, of ICHOM LCWG. Defining a standard set of patient-centered outcomes for lung cancer. Eur Respir J 48(3):852-60, 2016. e-Pub 2016. PMID: 27390281.
      54. Li R, Hermann G, Baldini E, Chen AB, Jackman D, Kozono D, Nguyen P, Nohria A, Powell G, Mak R. Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer. Lung Cancer 96:41-7, 2016. e-Pub 2016. PMID: 27133748.
      55. Chen RC, Hoffman KE, Sher DJ, Showalter TN, Morrell R, Chen AB, Benda R, Nguyen PL, Movsas B, Hardenbergh P. Development of a standard survivorship care plan template for radiation oncologists. Pract Radiat Oncol 6(1):57-65, 2016. e-Pub 2016. PMID: 26778795.
      56. Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, Wilson LD, Decker RH, Yu JB. Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage II and III non-small-cell lung cancer. J Clin Oncol 33(25):2727-34, 2015. e-Pub 2015. PMID: 26101240.
      57. Kehl KL, Landrum MB, Kahn KL, Gray SW, Chen AB, Keating NL. Tumor board participation among physicians caring for patients with lung or colorectal cancer. J Oncol Pract 11(3):e267-78, 2015. e-Pub 2015. PMID: 25922221.
      58. Baldini EH, Richards WG, Gill RR, Goodman BM, Winfrey OK, Eisen HM, Mak RH, Chen AB, Kozono DE, Bueno R, Sugarbaker DJ. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 149(5):1374-81, 2015. e-Pub 2015. PMID: 25772281.
      59. Mak RH, Hermann G, Lewis JH, Aerts HJ, Baldini EH, Chen AB, Colson YL, Hacker FH, Kozono D, Wee JO, Chen YH, Catalano PJ, Wong KK, Sher DJ. Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer 16(1):24-32, 2015. e-Pub 2015. PMID: 25450872.
      60. Hoopes DJ, Johnstone PA, Chapin PS, Kabban CM, Lee WR, Chen AB, Fraass BA, Skinner WJ, Marks LB. Practice patterns for peer review in radiation oncology. Pract Radiat Oncol 5(1):32-8, 2015. e-Pub 2015. PMID: 25413419.
      61. Chen AB, Li L, Cronin A, Schrag D. Comparative effectiveness of intensity-modulated versus 3D conformal radiation therapy among medicare patients with stage III lung cancer. J Thorac Oncol 9(12):1788-95, 2014. e-Pub 2014. PMID: 25226428.
      62. Chong CR, Wirth LJ, Nishino M, Chen AB, Sholl LM, Kulke MH, McNamee CJ, Jänne PA, Johnson BE. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer 86(2):241-6, 2014. e-Pub 2014. PMID: 25218177.
      63. Yip S, Chen AB, Aerts HJ, Berbeco R. Sensitivity study of voxel-based PET image comparison to image registration algorithms. Med Phys 41(11):111714, 2014. e-Pub 2014. PMID: 25370628.
      64. Gray PJ, Mak RH, Yeap BY, Cryer SK, Pinnell NE, Christianson LW, Sher DJ, Arvold ND, Baldini EH, Chen AB, Kozono DE, Swanson SJ, Jackman DM, Alexander BM. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer 85(2):239-44, 2014. e-Pub 2014. PMID: 24974152.
      65. Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, Lo PC, Baldini EH, Johnson BE, Chen AB. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 89(4):880-7, 2014. e-Pub 2014. PMID: 24867533.
      66. Gazula A, Baldini EH, Chen AB, Kozono D. Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer. Lung 192(1):151-8, 2014. e-Pub 2014. PMID: 24162870.
      67. Yip S, McCall K, Aristophanous M, Chen AB, Aerts HJ, Berbeco R. Comparison of texture features derived from static and respiratory-gated PET images in non-small cell lung cancer. PLoS One 9(12):e115510, 2014. e-Pub 2014. PMID: 25517987.
      68. Coroller TP, Mak RH, Lewis JH, Baldini EH, Chen AB, Colson YL, Hacker FL, Hermann G, Kozono D, Mannarino E, Molodowitch C, Wee JO, Sher DJ, Killoran JH. Low incidence of chest wall pain with a risk-adapted lung stereotactic body radiation therapy approach using three or five fractions based on chest wall dosimetry. PLoS One 9(4):e94859, 2014. e-Pub 2014. PMID: 24728448.
      69. Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, Schrag D. Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer. J Clin Oncol 31(21):2730-5, 2013. e-Pub 2013. PMID: 23775958.
      70. Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. Cancer 119(11):2048-60, 2013. e-Pub 2013. PMID: 23564469.
      71. Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, Schrag D. Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol 31(5):558-64, 2013. e-Pub 2013. PMID: 23295799.
      72. Chen AB, Feng Y, Neuberg D, Recklitis C, Diller LR, Mauch PN, Ng AK. Employment and insurance in survivors of Hodgkin lymphoma and their siblings: a questionnaire study. Leuk Lymphoma 53(8):1474-80, 2012. e-Pub 2012. PMID: 22280535.
      73. Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 307(15):1593-601, 2012. e-Pub 2012. PMID: 22511687.
      74. Aristophanous M, Yong Y, Yap JT, Killoran JH, Allen AM, Berbeco RI, Chen AB. Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans. Radiother Oncol 102(3):377-82, 2012. e-Pub 2012. PMID: 22265731.
      75. Aristophanous M, Berbeco RI, Killoran JH, Yap JT, Sher DJ, Allen AM, Larson E, Chen AB. Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning. Int J Radiat Oncol Biol Phys 82(1):e99-105, 2012. e-Pub 2012. PMID: 21377285.
      76. Sher DJ, Neville BA, Chen AB, Schrag D. Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis. Int J Radiat Oncol Biol Phys 81(4):e197-206, 2011. e-Pub 2011. PMID: 21596483.
      77. Aristophanous M, Yap JT, Killoran JH, Chen AB, Berbeco RI. Four-dimensional positron emission tomography: implications for dose painting of high-uptake regions. Int J Radiat Oncol Biol Phys 80(3):900-8, 2011. e-Pub 2011. PMID: 20950956.
      78. Chen AB, Neville BA, Sher DJ, Chen K, Schrag D. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol 29(17):2305-11, 2011. e-Pub 2011. PMID: 21537034.
      79. Rottmann J, Aristophanous M, Chen AB, Court L, Berbeco R. A multi-region algorithm for markerless beam's-eye view lung tumor tracking. Phys Med Biol 55(18):5585-98, 2010. e-Pub 2010. PMID: 20808029.
      80. Chen AB, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors. J Clin Oncol 27(32):5383-9, 2009. e-Pub 2009. PMID: 19752333.
      81. Chen AB, D'Amico AV, Neville BA, Steyerberg EW, Earle CC. Provider case volume and outcomes following prostate brachytherapy. J Urol 181(1):113-8; discussion 118, 2009. e-Pub 2009. PMID: 19012905.
      82. Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 24(33):5298-304, 2006. e-Pub 2006. PMID: 17114664.
      83. Rietzel E, Liu AK, Doppke KP, Wolfgang JA, Chen AB, Chen GT, Choi NC. Design of 4D treatment planning target volumes. Int J Radiat Oncol Biol Phys 66(1):287-95, 2006. e-Pub 2006. PMID: 16904528.
      84. Chen AB, Killoran J, Kim H, Mamon H. Treatment planning for resected abdominal tumors: Differences in organ position between diagnostic and radiation-planning computed tomography scans. Int J Radiat Oncol Biol Phys 63(5):1613-20, 2005. e-Pub 2005. PMID: 16115738.

      Invited Articles

      1. Chen AB, D’Amico AV, Earle CC. Complications following prostate brachytherapy. Am J Hematol Oncol 6(4s4):22-24, 2007. e-Pub 2007. PMID: 31479748.

      Review Articles

      1. Simone CB, Bradley J, Chen AB, Daly ME, Louie AV, Robinson CG, Videtic GMM, Rodrigues G. ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer. Pract Radiat Oncol 13(3):195-202, 2023. e-Pub 2023. PMID: 37080641.
      2. Jagsi R, Bekelman JE, Chen AB, Chen RC, Hoffman K, Shih YC, Smith BD, Yu JB. Considerations for observational research using large data sets in radiation oncology. Int J Radiat Oncol Biol Phys 90(1):11-24, 2014. e-Pub 2014. PMID: 25195986.

      Professional Educational Materials

      1. . Clinical pathways: non-small cell lung cancer. Dana-Farber/Brigham and Women's Cancer Center, 2018.
      2. . Clinical pathways: small-cell lung cancer. Dana-Farber/Brigham and Women's Cancer Center, 2018.
      3. . Guidelines for radiation therapy for lung cancers. Dana-Farber/Brigham and Women's Cancer Center, 2016.

      Other Articles

      1. Chen AB, Li L, Cronin A, Wind J, Schrag D Medicare spending in cancer: a SEER-Medicare analysis. Report to American Society of Radiation Oncology, 2016.

      Abstracts

      1. Alatrach M, Corrigan K, Andring LM, Peek A, Chang JY, Lee P, Lin SH, Ning MS, Nguyen QN, O'Reilly MS, Chen AB. Disparities in Completion of Patient-Reported Outcomes in Thoracic Radiation Oncology Patients 120(2):348-349, 2024.
      2. Marquez C, Pham N, Corrigan K, Andring L, Alatrach M, Moreno A, Hoffman K, Peek A, Liao Z, Chen A. Navigating perspectives: integration of patient-reported outcomes in patients receiving thoracic radiation 47(10):5-6. e-Pub 2024.
      3. Whisenant M, Yang Y, Weathers S, Chen A, Milbury K. Correlation between self-reported and proxy-reported cancer patient and caregiver symptoms. NINR/NCI/ONS symptom science symposium, 2021. e-Pub 2021.
      4. Chen JJ, Roldan C, Nichipor A, Balboni T, Krishnan M, Revette A, Chen A, Hertan L. Patient-Provider Communication and Decision-Making in Palliative Radiotherapy for Metastatic Cancer. Int J Radiat Oncol Biol Phys 108(2s), 2020. e-Pub 2020.
      5. Roldan CS, Chen JJ, Nichipor AN, Balboni TA, Krishnan MS, Revette A, Cheb AB, Hertan LM. Perceptions of Prognosis and Goals of Care in Patients Receiving Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys 108(2s):E66, 2020. e-Pub 2020.
      6. Chen JJ, Roldan CS, Nichipor AN, Balboni TA, Krishnan MS, Revette A, Hertan LM, Chen AB. Patient-provider communication an decision making in palliative radiotherapy. J Clin Oncol 37(31):24, 2019. e-Pub 2019.
      7. Roldan CS, Chen JJ, Nichipor AN, Balboni TA, Krishnan MS, Revette A, Cheb AB, Hertan LM. Perceptions of prognosis and goals of care in patients receiving radiation therapy. J Clin Oncol 37(31):30, 2019. e-Pub 2019.
      8. Raldow A, Chen AB, Lee P, Russell M, Hong TS, Ryan DP, Wo JY. Cost-effectiveness of short course radiation therapy versus long-course chemoradiation for locally advanced rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 102(3):S1160, #329, 2018. e-Pub 2018.
      9. Milligan M, Cronin AM, Li L, Colson Y, Kehl K, Chen AB. Overuse of diagnostic brain imaging among patients with stage IA non-small cell lung cancer. Int J Radiat Oncol Biol Phys 102(3):e420-e421 #TU_9_2985, 2018. e-Pub 2018.
      10. Chen AB, Cronin AM, Schrag D. Variation in use of palliative radiation in lung cancer patients with bone metastases by health care market. Int J Radiat Oncol Biol Phys 102(3):Suppl 3, #1016, 2018. e-Pub 2018.
      11. Chen AB, Li L, Cronin A, Brooks G, Kavanagh B, Schrag D. Total medicare and radiation-specific costs during a palliative "radiation episode". Int J Radiat Oncol Biol Phys 96(2):S136 #306, 2016. e-Pub 2016.
      12. Mak KS, van Bommel AC, Stowell C, Abrahm JL, Baker M, Baldotto CS, Balwein DR, Borthwick D, Carbone DP, Chen AB, Haswell T, Koczywas M, Kozower BD, Mehran RJ, Schramel FM, Senan S, Stirling RG, van Meerbeeck JP, Wouters MW, Peaker MD. Defining a standard set of patient centered outcomes for patients with lung cancer. Int J Radiat Oncol Biol Phys 93(3):#3004, 2016. e-Pub 2016. PMID: 27390281.
      13. Mak RH, Hermann G, Aerts H, Chen AB, Baldini E, Kozono DE, Chen YH, Catalano PJ, Janne P. Outcomes by EDFR, FRAS, and ALK genotype after combined modality therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 96:#352, 2016. e-Pub 2016.
      14. Chen AB, Li L, Cronin A, Brooks G, Kavanagh B, Schrag D. How should we estimate costs of care attributable to cancer?. J Clin Oncol 33:#6503, 2015. e-Pub 2015.
      15. Kim M, Schrag D, Li L, Chen AB. Predictors of use of radiation therapy (RT) among medicare patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 33:#6503, 2015. e-Pub 2015.
      16. Hou Y, Chen AB, Kozono D, Killoran J, Wagar M, Lee S, Hacker F, Aerts H, Lewis J, Mak R. Cone beam computed tomography (CBCT) inter-scan and inter-observer tumor volume variability assessment in patients treated with stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC). Med Phys 42(6):(abstr SU-E-J-266), 2015. e-Pub 2015.
      17. Yip S, McCall K, Aristophanous M, Chen AB, Aerts H, Berbeco R. The effect of respiratory motion on pet imaging of tumor heterogeneity in non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 90(1):Suppl S25-S26 #47, 2014. e-Pub 2014.
      18. Hou Y, Hermann G, Lewis JH, Aerts HJ, Baldini EH, Chen AB, Colson YL, Hacker FL, Hilloran J, Kozono DE, Wee JO, Mak RH. Outcomes and toxicity after lung stereotactic body radiation therapy (SBRT in patients (Pts) with a history of prior lung resection for radiofrequency ablation (RFA). Int J Radiat Oncol Biol Phys 90(1):S660 #3140, 2014. e-Pub 2014.
      19. Mak KS, Mannarino EG, Richards WG, Mak RH, Chen AB, Kozono E, Gill RR, Sugarbaker DJ, Beldini E. Patterns of local recurrence for mesothelioma patients treated with extra-pleural pneumonectomy (and radiation therapy using the electron-photon technique: the dosimetric challenges of electron-photon match lines and blocks. Int J Radiat Oncol Biol Phys 90(1s):#3010, 2014. e-Pub 2014.
      20. Yip S, Chen AB. Sensitivity of PET-based texture features to respirator motion in non-small cell lung cancer (NSCLC) patients. Med Phys 41(6):(abstr MO-G-BRF-1), 2014. e-Pub 2014.

      Book Chapters

      1. Allen CJ, Chen A, Huey R, Shi YT. Value-based oncology. In: The MD Anderson Manual of Medical Oncology, 2022.
      2. Milligan M, Chen AB. Population and outcomes research: study design. In: Handbook of Clinical Cancer Research, 2018.
      3. Chen AB. Comparative effectiveness research in radiation oncology: assessing technology. In: Semin Radiat Oncol. 25-34, 2014.

      Letters to the Editor

      1. Chen AB. In reply to Lo et al. Int J Radiat Oncol Biol Phys 15: 880-881, 2015.
      2. Jagsi R, Bekelman JE, Chen AB, Chen RC, Hoffman K, Shih YC, Smith BD, Yu JB. In reply to Rusthoven and Kavanagh. Int J Radiat Oncol Biol Phys, 2015.
      3. Chen AB, Schrag D. Reply to F. Fiorica et al and D. Vordermark. J Clin Oncol 31: 2759-2760, 2013.
      4. Chen AB, Schrag D. Reply to Koshy. J Clin Oncol 29: 3587-3588, 2011.
      5. Chen AB, Schrag D. Reply to Levy. J Clin Oncol 29: 4336-, 2011.
      Read More
      Less

      Patient Reviews


      CV information above last modified September 11, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top